Novartis Hellas: The Prescription Target Behind the Congress Trip

In the Novartis Hellas FCPA case, parent company Novartis AG agreed to a $112,800,000 SEC settlement over false records and failed accounting controls, including schemes to buy prescriptions in Greece. Under its separate criminal deferred prosecution agreement, the Greek subsidiary admitted using congress travel and study payments to increase prescribing. If you worked with sponsorship budgets, doctor rankings or study accounts, the telling detail may be familiar: an expense described as medical education came with a sales target.

Novartis Hellas sold and marketed Novartis prescription drugs throughout Greece. The Athens-based company was an indirect wholly owned subsidiary of Novartis AG, and its financial statements fed into the parent’s accounts. The Swiss parent’s securities traded on the New York Stock Exchange. The local sales instructions and the parent’s published books were parts of the same business.

Under its criminal deferred prosecution agreement, Novartis Hellas admitted bribing employees of state-owned and state-controlled hospitals and clinics through international congress travel between 2012 and 2015. The Justice Department’s account of those admissions also describes improper epidemiological-study payments during 2009 and 2010. Both arrangements sought more prescriptions, and the company admitted causing the payments to be falsely recorded in its parent’s books.

What Conduct Can Violate the FCPA?

Buying prescriptions from public-hospital doctors through paid travel can violate the Foreign Corrupt Practices Act. Novartis Hellas admitted that conduct under its criminal deferred prosecution agreement. The company paid for Greek public-sector health care providers to attend international medical congresses in exchange for increased Lucentis prescribing. Its employees traveled to the United States and facilitated improper benefits there, according to the Justice Department’s account.

Lucentis treated wet age-related macular degeneration, among other conditions. The Securities and Exchange Commission alleged that Novartis Greece’s ophthalmology business used educational and scientific activities to deliver improper benefits, with brand and sales managers approving the activities and directing staff. As the Commission described it, this was a system managed inside the business, down to instructions about particular prescribers.

The public-hospital setting matters. In its 2015 pharmaceutical-industry remarks on foreign bribery and internal controls, the Commission’s enforcement director described sales representatives’ regular contact with doctors, pharmacists and administrators who help decide what public hospitals buy. Those employees can be foreign officials, putting the sales relationship directly alongside public purchasing power. In the Greek admissions, the benefit reached the person writing the prescription.

Congress Sponsorship Followed the Doctor’s Sales Value

The Commission’s settled order described a ranking system based on doctors’ prescribing preferences and volume. Employees allegedly chose benefits according to the doctor’s likelihood of prescribing Novartis products, planned around the expected return, and reduced or ended support when the prescriptions fell short. Doctors were allegedly reminded of the company’s investment and an obligation to prescribe.

According to the order, Novartis Greece targeted doctors it designated key opinion leaders and paid for congress attendance. Internal meeting minutes discussed canceling participation in congresses in the United States and Europe unless sales performance improved significantly. A sales representative had something concrete to offer and something concrete to withdraw.

The order reproduced the message an ophthalmology manager planned to deliver in a 2013 action plan:

We see a sales bargain stated in the manager’s own words. A program presented as support for medical knowledge had a commercial test: would the doctor write the prescriptions? The action plan supplied the meaning that a congress invoice could leave out.

The order also alleged that sales representatives demanded non-use of a competitor’s product and full cooperation in exchange for considering a doubled gift. The order said doctors with less prescribing potential were excluded from sponsorships and other supposedly educational activities. That put the competitor up against a benefit conditioned on keeping its medicine out.

This is the practical connection between pharmaceutical sponsorship and prescription buying. The invitation, the doctor’s sales ranking and the manager’s conditions describe the same transaction from different desks. An employee who knows why support was renewed or canceled can explain what the expense description does not.

EXACTLY Put Research Payments Behind the Same Sales Goal

The EXACTLY epidemiological study gave the company another way to pay healthcare providers. The Justice Department’s account of the criminal admissions says employees knew that many participants believed the payments rewarded prescriptions rather than the provision of study data. The order adds the participant-selection, scientific-review and accounting details that make that mismatch visible.

The order explains that Phase IV clinical studies were supposed to assess a prescription drug’s safety and efficacy and publish results to inform medical decisions. Medical Affairs was supposed to select participating providers. In some instances, the Commission alleged, sales personnel selected them instead to promote products or increase prescribing.

That distinction reaches the design of the activity. Medical Affairs had a scientific reason to choose participants, while sales had a reason to choose people who could move product. For an insider, who chose the doctors can explain why a study operated the way it did, before any payment is examined.

The Audit Questioned the Science

A 2012 internal audit, described in the SEC order, identified unsupported medical or scientific reasons for studies and indications that they served promotional purposes. The auditors also found weaknesses in collecting data and publishing results, together with limited transparency outside Medical Affairs. Novartis Greece agreed to improve finance’s oversight in response.

According to the order, corporate security reached similar conclusions in a review that included EXACTLY. It also found that some provider payments went through a vendor named “dummy vendor.” For an employee who knew the participants, that vendor entry could obscure the connection between a doctor and a study payment.

The Forms and the Debrief Told Different Stories

The order reported mistakes in 25,500 of the 42,000 clinical research forms submitted. It also described a recorded debrief after EXACTLY in which employees discussed doctors’ belief that their prescriptions, rather than their research work, earned the payments. The recording gave the payment arrangement a meaning the forms alone could not supply:

The order described some providers receiving approximately 60 euros per patient form. Set beside the debrief, those payments make the insider’s knowledge consequential: what did the company expect the doctor to deliver? The nominal unit of payment was a form, while employees were discussing the prescription business behind it.

The Order Described Sales Targets and a Finance Black Box

According to the Commission’s order, finance described clinical studies as a “black box.” It lacked visibility into study budgets, and there was no proper reconciliation between approved budgets and actual spending. The order also described dummy vendors used in attempts to track which providers were paid for which studies and how the payments compared with the budget.

We see an extraordinary imbalance in those accounts. In the order’s account, the ophthalmology sales operation could rank doctors and reduce benefits when prescribing disappointed, while finance could not properly reconcile the clinical-study spending. Commercial expectations were explicit in one set of records, and the use of the money remained obscure in another.

The Commission alleged that Novartis Greece recorded the improper payments as ordinary advertising and promotion or marketing and sales expenses. Because the subsidiary’s financial statements were consolidated into the parent’s, the descriptions traveled into Novartis AG’s accounts. The books-and-records problem connected the local payment to what the parent reported.

The order also described a separate grant review that found incomplete checks on recipients, unclear uses of funds and improper connections to sales strategies. The sales connection extended beyond congress sponsorships and studies into another category of spending.

A Different Healthcare Channel, the Same Commercial Condition

Fresenius Medical Care illustrates how a benefit tied to doctors’ business can take another form. In its settled order concerning Fresenius, the Securities and Exchange Commission alleged that publicly employed Turkish doctors received joint-venture shares without contributing capital in exchange for directing business from their public employers to Fresenius clinics. The order also described a doctor’s equity purchase price tied to the number of patients at the clinic.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA found that employees kept working around controls despite flagged transactions and company policies. We take a practical point from that analysis: an audit warning matters, but so does what the business keeps paying for. In the Novartis account, that means reading the study reviews alongside the separate sponsorship and grant records.

The comparison concerns what the benefit bought. In the Greek criminal admissions it was prescribing, while the Turkish conduct alleged in the Fresenius order involved patient referrals and equity. Different paperwork can still place the doctor’s financial benefit next to the business the company expects back.

The Civil Settlement Belonged to the Parent

Novartis AG’s June 25, 2020 settlement with the Securities and Exchange Commission covered alleged failures across several markets, including Greece, Korea, Vietnam and the former Alcon business in China. The parent’s civil foreign-bribery settlement was separate from the criminal agreements entered by Novartis Hellas and Alcon Pte Ltd.

The Commission attributed more than $70.1 million in unjust enrichment to Greek sales of Lucentis and products associated with OBVIOUS and REGINA. The order put many congress sponsorships at more than $5,000 per doctor. We see the commercial bargain in those different scales: a travel budget for the prescriber, a far larger return for the company.

What an Insider Can Recognize in the Records

The Novartis Hellas doctor travel scheme shows why a whistleblower case can depend on the link between sponsorship decisions and company accounts. Prescriber rankings, congress plans, meeting minutes, study reviews and payment accounts describe the arrangement from different positions inside the company. The case shows how evidence connects a commercial decision to a benefit and its accounting description. You may know one of those connections from your own work, even if another department handled the rest. We start with what you know and work through those connections with you.

A sales employee may understand why a doctor’s congress support depended on prescription volume. A study coordinator may know who selected the participants and what the completed forms represented. An accounting employee may recognize the vendor entry or the gap between an approved budget and the actual spending. A payment approval is much more informative when someone can explain the transaction behind it.

The Securities and Exchange Commission’s whistleblower program can pay eligible whistleblowers a combined 10% to 30% of qualifying money collected. We assess the foreign-bribery whistleblower programs against the conduct and information you know. A separate whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We distinguish those programs with you as part of building the case strategy.

You Know Why the Doctor Got the Trip

If you saw a sponsorship promise, study payment or grant tied to prescriptions, speak to one of our Whistleblower Experts about the sales expectation behind it. We build the case with you and bring in pharmaceutical foreign-bribery whistleblower lawyers who understand the links between public-sector doctors, commercial incentives and company accounts. We stay with you as your knowledge becomes a case strategy and through the decisions that follow.